| Literature DB >> 24708568 |
Axel Josefsson1, Michael Fu, Einar Björnsson, Evangelos Kalaitzakis.
Abstract
BACKGROUND: Although cardiovascular disease is thouht to be common in cirrhosis, there are no systematic investigations on the prevalence of electrocardiographic (ECG) abnormalities in these patients and data on the occurrence of post-transplant cardiac events in comparison with the general population are lacking. We aimed to study the prevalence and predictors of ECG abnormalities in patients with cirrhosis undergoing liver transplantation and to define the risk of cardiac events post-transplant compared to the general population.Entities:
Mesh:
Year: 2014 PMID: 24708568 PMCID: PMC4009062 DOI: 10.1186/1471-230X-14-65
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Baseline characteristics of all patients with cirrhosis included in the study (n = 234) and those with an available ECG from pre-transplant evaluation (n = 186)
| 52 (10.5) | 52 (11) | |
| 162 (69%) | 133 (72%) | |
| | | |
| Alcoholic liver disease or mixed | 85 (36%) | 71 (38%) |
| Viral liver disease | 55 (23.5%)1 | 47 (25.5%)2 |
| Cholestatic liver disease | 42 (18%)3 | 33 (18%)4 |
| Autoimmune hepatitis | 14 (6%) | 12 (6.5%) |
| Cryptogenic/NASH cirrhosis | 20 (8.5%) | 18 (9.5%) |
| Other | 18 (8%)5 | 5 (2.5%) |
| | | |
| Child Pugh Score | 9 (2.2) | 8.9 (2.2) |
| MELD | 16.5 (6.8) | 16.2 (6.5) |
| | | |
| History of variceal bleeding | 59 (25%) | 45 (24%) |
| Ascites at evaluation | 167 (71%) | 132 (71%) |
| Hepatocellular carcinoma in explant | 26 (11%) | 23 (12.5%) |
| Hepatorenal syndrome | 43 (18%) | 33 (17.5%) |
| 85.5 (12) | 85 (11.5) | |
| 72 (11) | 72 (12) | |
| 83 (29.5) | 83 (29.5) | |
| 18 (8%) | 13 (7%) | |
| 28 (12%) | 37 (20%) | |
| 48 (20%) | 23 (12%) | |
| 118 (43%) | 92 (49%) | |
| 112 (48%) | 92 (49%) | |
| 152 (65%) | 123 (66%) | |
| 95 (34.5%) | 74 (40%) |
Data expressed as mean (SD) or n (%) as appropriate. No statistical difference was seen between the groups with regard to the factors listed in this table. (p > 0.1 for all).
NASH, non-alcoholic steatohepatitis; MELD, model for end-stage liver disease; CAD, Coronary artery disease.
1Hepatitis C – 30, Hepatitis B - 21, Hepatitis B and C - 4.
2Hepatitis C - 38, hepatitis B - 28, hepatitis C and hepatitis B – 5.
3Primary sclerosing cholangitis - 20, Primary biliary cirrhosis – 13.
4Primary sclerosing cholangitis - 26, Primary biliary cirrhosis - 17.
5Overlap syndrome - 7, Alpha 1 antitrypsine deficiency – 3, Cholestatic disease and alcoholic liver disease – 2, Secondary sclerosing cholangitis - 2, Wilsons disease - 1, Drug induced liver injury - 1, Cystic fibrosis - 1, and Echinococcal infection/treatment of echinococcal infection - 1.
6Patients who underwent further investigation for CAD at pre-transplant evaluation such as coronary angiography, myocardial scintigraphy, stress echocardiography and/or treadmill exercise test.
Demographic and ECG data in patients with liver cirrhosis at pre-transplant evaluation (with an available ECG) and healthy controls
| 52 (11) | 51 (11) | 0.4 | |
| 134 (71.5%) | 61 (62%) | 0.104 | |
| 92/173 (53%) | 30/59 (51%) | 0.699 | |
| | | | |
| Systolic (mmHg) | 119 (17.5) | 126 (19.5) | 0.004 |
| Diastolic (mmHg) | 68 (11) | 77 (11.5) | <0.001 |
| 6.7 (3.5) | 5.0 (0.8) | <0.001 | |
| 25.4 (4.5) | 25.5 (3.5) | 0.88 | |
| 0.429 (0.032) | 0.406 (0.037) | <0.001 | |
| Prolonged QT interval | 57 (31.5%) | 8 (8%) | <0.001 |
| 23 (12%) | 1 (1%) | 0.001 | |
| 39 (21%) | 10 (10%) | 0.022 | |
| Left axis deviation (−30° - -90°) | 33 (18%) | 7 (7%) | 0.015 |
| Right axis deviation (+120° - -150°) | 2 (1%) | 0 (0%) | 0.304 |
| Indeterminate axis QRS axis approximately +90° from the frontal plane | 1 (0.5%) | 2 (2%) | 0.237 |
| 17 (9%) | 5 (5%) | 0.226 | |
| 10 (5%) | 0 (0%) | 0.019 | |
| 19 (10%) | 4 (4%) | 0.072 | |
| 13 (7%) | 3 (3%) | 0.172 | |
| AV- Block 1 | 10 (5%) | 3 (3%) | 0.375 |
| Short PR interval | 2 (1%) | 0 (0%) | 0.303 |
| High grade AV block | 1 (0.5%) | 0 (0%) | 0.467 |
| 18 (10%) | 10 (10%) | 0.887 | |
| Right bundle branch block | 2 (1%) | 0 (0%) | 0.304 |
| Incomplete right bundle branch block | 6 (3%) | 1 (1%) | 0.257 |
| Intraventricular block | 1 (0.5%) | 0 (0%) | 0.468 |
| R-R’ pattern in either of leads V1, V2 with R’ amplitude ≥ R | 3 (1.5%) | 7 (7%) | 0.016 |
| Incomplete left bundle branch block or RR’ | 6 (3%) | 2 (2%) | 0.571 |
| 13 (7%) | 8 (8%) | 0.719 | |
| Presence of frequent atrial or junctional premature beats (≥10% of recorded complexes) | 1 (0.5%) | 0 (0%) | 0.467 |
| Atrial flutter or fibrillation | 4 (2%) | 0 (0%) | 0.144 |
| Sinus tachycardia (heart rate > 100/min) | 3 (1.5%) | 0 (0%) | 0.206 |
| Sinus Bradycardia (heart rate < 50/min) | 4 (2%) | 8 (8%) | 0.017 |
| Other arrhythmias | 1 (0.5%) | 0 (0%) | 0.467 |
| 61 (33%) | 71 (72%) | <0.001 | |
| QRS transition zone to the right of lead V3 | 16 (9%) | 0 (0%) | 0.003 |
| QRS transition zone to the left of lead V3 | 43 (23%) | 71 (72%) | <0.001 |
| 40 (17%) | 5 (5%) | <0.001 |
Data is expressed as n (%) or as mean (SD) as appropriate.
AV; Atrioventricular, CAD; Coronary artery disease.
1Data were not available in all patients and controls.
2The QT interval was corrected according to the Bazett formula (16).
3Q wave, T wave inversion and/or ST-depression (17, 18).
Factors related to ECG abnormalities in patients with cirrhosis at pre-transplant evaluation in multivariate logistic regression analysis (n = 186)
| Possible QT prolonging drug1 | 5.84 (1.87-18.22) | |
| Alcoholic cirrhosis | 2.99 (1.25-7.18) | |
| Age (years) | 1.06 (1.01-1.10) | |
| Mean arterial pressure | 0.94 (0.90-.0.97) | |
| Propranolol | 0.25 (0.1-0.65) | |
| MELD score (per 1 unit) | 1.08 (1.02–1.16) | |
| Age (per year) | 1.12 (1.04-1.20) | |
| History of arterial hypertension (if yes) | 3.14 (1.16-8.47) | |
| Male sex (if yes) | 4.40 (1.25-15.43) | |
| History of arterial hypertension (if yes) | 7.00 (1.30-37.84) | |
| Cholestatic liver disease (if yes) | 6.10 (1.24-30.15) | |
| MELD score (per 1 unit) | 1.08 (1.02-1.14) | |
| Age (per year) | 1.05 (1.01-1.09) | |
| Viral liver disease (if yes) | 0.26 (0.08-0.84) |
GFR, Glomerular filtration rate; MELD, Model of end stage liver disease; CAD, Coronary artery disease.
1Flouroquinolones - 19, Selective serotonin re-uptake inhibitors - 10, Quinine - 6, Prepulside - 1.
2Q wave, T wave inversion and/or ST-depression (17, 18).
Standardized incidence ratios for cardiac events in patients with cirrhosis (n = 234) following liver transplantation
| Total cardiac events3 | 728.9 | 70 | 13.96 | 5.014 | 3.909 - 6.335 | <0.001 |
| Total acute coronary syndromes3 | 728.9 | 16 | 4.336 | 3.69 | 2.109 - 5.992 | <0.001 |
| Total arrhythmic events3 | 728.9 | 49 | 9.624 | 5.091 | 3.767 - 6.731 | <0.001 |
| Late cardiac events4 | 846.0 | 31 | 17.1 | 1.813 | 1.232 - 2.573 | 0.003 |
| Late acute coronary syndrome4 | 846.0 | 13 | 5.264 | 2.469 | 1.315 - 4.223 | 0.006 |
| Late arrhythmic events4 | 846.0 | 14 | 11.84 | 1.183 | 0.647 - 1.984 | 0.603 |
SIR, Standardized incidence ratio; CI, Confidence interval. For the calculation of SIRs, data on the occurrence of cardiac events in the general Swedish population were obtained from the national inpatient hospital registry.
1Observed events; the number of observed events in our cohort.
2Expected events; the number of events that occurred in the age and gender matched group of the general population.
3All events occurring after liver transplantation until death or end of follow-up.
4All events occurring after the immediate inpatient post-transplant period.
Post-transplant outcome of patients with liver cirrhosis with an available ECG at pre-transplant evaluation (n = 186)
| Cardiac events | 31 (17%) |
| ACS | 1 (0.5%) |
| Arrhythmia | 24 (13%) |
| Other1 | 3 (1.5%) |
| Mortality | 8 (4%) |
| Mortality due to a direct cardiac cause | 3 (1.5%) |
| Retransplantation | 8 (4%) |
| | |
| Cardiac events | 27 (14.5%) |
| ACS | 12 (6.5%) |
| Arrhythmia | 12 (6.5%) |
| Mortality | 40 (21.5%) |
| Mortality due to a direct cardiac cause | 3 (1.5%) |
| Retransplantation | 9 (5%) |
| | |
| Cardiac events | 54 (29%) |
| ACS | 13 (7%) |
| Arrhythmia | 36 (19.5%) |
| Mortality | 48 (26%) |
| Mortality due to a direct cardiac cause2 | 6 (3%) |
| Retransplantation | 17 (9%) |
| Mortality and retransplantation | 56 (30%) |
Data is presented as n (%).
Some patients had both a peri-transplant event and a late event.
ACS, Acute coronary syndrome.
1Acute circulatory failure without known cause and sudden cardiac arrest.
2Acute coronary syndromes - 4, Sudden cardiac arrest - 1, Acute circulatory failure - 1.
Figure 1Cardiac events and ECG abnormalities. a-e. Relation between frequently occurring pre-transplant ECG abnormalities in patients with cirrhosis and post-transplant cardiac events (n = 186).